Repositioning Candidate Details

Candidate ID: R0230
Source ID: DB00657
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Mecamylamine
Synonyms: Mecamylamine
Molecular Formula: C11H21N
SMILES: CNC1(C)C2CCC(C2)C1(C)C
Structure:
DrugBank Description: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
CAS Number: 60-40-2
Molecular Weight: 167.2911
DrugBank Indication: For the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension
DrugBank Pharmacology: Mecamylamine is a potent, oral antihypertensive agent and ganglion blocker, and is a secondary amine. Mecamylamine is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. Mecamylamine reduces blood pressure in both normotensive and hypertensive individuals. A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced. Mecamylamine crosses the blood-brain and placental barriers.
DrugBank MoA: Mecamylamine is a ganglionic blocker which prevents stimulation of postsynaptic receptors by acetylcholine released from presynaptic nerve endings. The hypotensive effect of Mecamylamine is attributed to reduction in sympathetic tone, vasodilation, and reduced cardiac output, and is primarily postural.
Targets: Neuronal acetylcholine receptor subunit alpha-2 antagonist; Neuronal acetylcholine receptor subunit alpha-7; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2
Inclusion Criteria: Therapeutic strategy associated